Will there be a Registration Obligation for critical Medical Devices?
Following the PIP scandal (See our GMP News from 22. February) the EU currently deals more intensively with the planned revision of medical devices regulation. In a resolution the European Parliament has now proposed various measures to eliminate the "system's malfunctions on a European and a national level". The following measures are currently being discussed:
- Introduction of a "pre-market authorisation" system for certain medical devices, including breast implants - comparable to medicinal products
- Introduction of an implant pass comprising specific characteristics of the implant as well as possible side effects
- Introduction of a breast implant register
- Increased market surveillance (including inspections)
- Establishment of a European database for medical devices which will comprise information on medical devices currently on the market - like monitoring data, clinical studies, information of designated authorities, EU certificates
The EU Commission with commissioner Dalli is objecting to the first measure. For the commission the introduction of an "authorisation system" bears the risk of an "overregulation" for medical devices that would also impede innovations. Dalli instead prefers a more stringent market monitoring. It will be interesting to see in what direction medical devices regulation will move.
More details with regard to the parliamentarians' suggestions are available in the EU press release "Breast implants: Parliament proposes stricter safety checks."
Compiled by
Sven Pommeranz
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
10.09.2025Artificial Intelligence in Medical Devices - the Perspective of Notified Bodies
10.09.2025The small but significant Difference between EN 13485 and EN ISO 13485
10.09.2025Audits of Medical Device Importers
21.01.2025FDA Warning Letter Statistics on Medical Devices in the past Fiscal Year
21.01.2025Artificial Intelligence in Medical Devices - Notified Bodies' Point of View
21.01.2025New FDA Guidance on Risk Analyses for Drugs, Biologics and Combination Products